elementbiosciences.comHealthcare / BioTech & PharmaFounded: 2017Funding to Date: $1.5B
Element Biosciences is a company in the life sciences industry that focuses on genetic analysis methodology. Element Biosciences was founded in 2017 and is headquartered in San Diego, CA. The company provides access to advanced biological tools that strive to enable researchers to accelerate scientific discoveries. Specifically, Element Biosciences develops innovative DNA sequencing and multi-omics technology for biosciences research. The company's proprietary technology is called the AVITI system, and it offers high-quality sequencing intending to be at a lower cost than alternative methods.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
07/11/2024 | Series D | $138.5MM | $xx.xx | $1.05B | Fidelity, Foresite Capital, Samsung Electronics, T. Rowe Price Associates, Venrock, Wellington Management | |
Price per Share
$xx.xx
Shares Outstanding
36,039,921
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Fidelity, Foresite Capital, Samsung Electronics, T. Rowe Price Associates, Venrock, Wellington Management
|
||||||
07/11/2024 | Series D-1 | $138.5MM | $xx.xx | $1.05B | Fidelity, Foresite Capital, Samsung Electronics, T. Rowe Price Associates, Venrock, Wellington Management | |
Price per Share
$xx.xx
Shares Outstanding
36,039,921
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Fidelity, Foresite Capital, Samsung Electronics, T. Rowe Price Associates, Venrock, Wellington Management
|
||||||
06/29/2021 | Series C | $277.52MM | $xx.xx | $1.61B | Counterpoint Global, Fidelity, Foresite Capital, Janus Henderson, Js Capital Llc, Logos Capital, Meritech Capital Partners, Ra Capital Management, T. Rowe Price, Venrock | |
Price per Share
$xx.xx
Shares Outstanding
13,500,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.2x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Counterpoint Global, Fidelity, Foresite Capital, Janus Henderson, Js Capital Llc, Logos Capital, Meritech Capital Partners, Ra Capital Management, T. Rowe Price, Venrock
|
||||||
01/09/2020 | Series B | $110.3MM | $xx.xx | $333.75MM | Fidelity, Foresite Capital, Js Capital Llc, Venrock | |
Price per Share
$xx.xx
Shares Outstanding
21,047,201
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Fidelity, Foresite Capital, Js Capital Llc, Venrock
|
||||||
06/18/2019 | Series A | $15MM | $xx.xx | $56.41MM | Foresite Capital, Venrock | |
Price per Share
$xx.xx
Shares Outstanding
8,299,215
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Foresite Capital, Venrock
|
||||||
09/11/2017 | Series Seed | $5.11MM | $xx.xx | $11.35MM | Foresite Capital | |
Price per Share
$xx.xx
Shares Outstanding
8,865,115
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Foresite Capital
|